Correlation Engine 2.0
Clear Search sequence regions


  • 1B1 (1)
  • adult (1)
  • anion (3)
  • cholesterol (1)
  • CYP3A (2)
  • CYP3A4 (7)
  • cyp3a4 protein, human (1)
  • CYP3A5 (4)
  • cyp3a5 protein, human (1)
  • female (1)
  • genotypes (1)
  • had (2)
  • humans (1)
  • linear models (1)
  • male (1)
  • P 450 (2)
  • P450 (2)
  • plasma (8)
  • profiles (1)
  • protein human (3)
  • risk benefit (1)
  • simvastatin (15)
  • simvastatin acid (13)
  • SLCO1B1 (8)
  • transport (1)
  • Sizes of these terms reflect their relevance to your search.

    Our objective was to evaluate the associations of genetic variants affecting simvastatin (SV) and simvastatin acid (SVA) metabolism [the gene encoding cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)*22 and the gene encoding cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5)*3] and transport [the gene encoding solute carrier organic anion transporter family member 1B1 (SLCO1B1) T521C] with 12-hour plasma SV and SVA concentrations. The variants were genotyped, and the concentrations were quantified by high performance liquid chromatography-tandem mass spectrometry in 646 participants of the Cholesterol and Pharmacogenetics clinical trial of 40 mg/d SV for 6 weeks. The genetic variants were tested for association with 12-hour plasma SV, SVA, or the SVA/SV ratio using general linear models. CYP3A5*3 was not significantly associated with 12-hour plasma SV or SVA concentration. CYP3A4*1/*22 participants had 58% higher 12-hour plasma SV concentration compared with CYP3A4*1/*1 participants (P = 0.006). SLCO1B1 521T/C and 521C/C participants had 71% (P < 0.001) and 248% (P < 0.001) higher 12-hour plasma SVA compared with SLCO1B1 521T/T participants, respectively. CYP3A4 and SLCO1B1 genotypes combined categorized participants into low (<1), intermediate (≈1), and high (>1) SVA/SV ratio groups (P = 0.001). In conclusion, CYP3A4*22 and SLCO1B1 521C were significantly associated with increased 12-hour plasma SV and SVA concentrations, respectively. CYP3A5*3 was not significantly associated with 12-hour plasma SV or SVA concentrations. The combination of CYP3A4*22 and SLCO1B1 521C was significantly associated with SVA/SV ratio, which may translate into different clinical SV risk/benefit profiles.

    Citation

    Jasmine A Luzum, Elizabeth Theusch, Kent D Taylor, Ann Wang, Wolfgang Sadee, Philip F Binkley, Ronald M Krauss, Marisa W Medina, Joseph P Kitzmiller. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. Journal of cardiovascular pharmacology. 2015 Jul;66(1):80-5

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 26164721

    View Full Text